Annual Evaluation and Performance Measurement Report (I.14- MYCOPLASMA GENTALIUM (MG))

Annually, each funded laboratory is required to report to CDC evaluation and performance measures. Data are used to indicate progress made toward program outcomes. These summary reports have to be uploaded to the ELC CAMP at the end of each funding year. Required performance measures are listed below.

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|

|  |  |  |
| --- | --- | --- |
|  | **Urogenital/Urine** | **Rectal** |
|   | **Male** | **Female** | **Male** | **Female** |
| **Number of specimens submitted by participating sites for MG identification via NAAT** | #  | # | #  | # |
| **Number of submitted specimens positive for MG** | # | # | # | # |
| **Number of MG-positive specimens tested for macrolide resistance associated mutations** | # | # | # | # |
| **Number of MG-positive specimens positive for macrolide resistance associated mutations** | # | # | # | # |
| **Number of MG-positive specimens tested for fluroquinolone resistance associated mutations** | # | # | # | # |
| **Number of MG-positive specimens positive for fluroquinolone resistance associated mutations** | # | # | # | # |
|  **% of results reported within required timeframe** | % | % | % | % |

 |